The Obama administration issued a new rule this month that
requires the makers of prescription drugs and other medical products to
disclose what they pay doctors for various purposes, like consulting or
speaking on behalf of the manufacturer. This overdue rule adds much-needed
weight to previous, more limited disclosure requirements.
The goal is to let the public know about payments that might
lead doctors to prescribe treatments that benefit them financially without
necessarily benefiting patients.
This information will allow patients and their families to
check whether their own doctors are receiving payments and to see if those
financial connections affect a doctor’s recommendation for a particular
treatment or device. (Más)
Ver también:
Ver también:
Entradas
No hay comentarios:
Publicar un comentario